Bone Biologics Corp Stock Z Score
| BBLG Stock | USD 1.31 0.06 4.80% |
Bone | Z Score |
Bone Biologics Corp Company Z Score Analysis
Bone Biologics' Z-Score is a simple linear, multi-factor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..
| |||||||
| |||||||
| |||||||
| |||||||
|
Bone Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Bone Biologics is extremely important. It helps to project a fair market value of Bone Stock properly, considering its historical fundamentals such as Z Score. Since Bone Biologics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bone Biologics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bone Biologics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate a Z-Score, one would need to know a company's current working capital, its total assets and liabilities, and the amount of its latest earnings as well as earnings before interest and tax. Z-Scores can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with Z-Scores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a so-called 'grey area,' with scores of less than 1 indicating the highest probability of distress. Z Score is a used widely measure by financial auditors, accountants, money managers, loan processors, wealth advisers, and day traders. In the last 25 years, many financial models that utilize z-scores proved it to be successful as a predictor of corporate bankruptcy.
| Competition |
In accordance with the company's disclosures, Bone Biologics Corp has a Z Score of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The z score for all United States stocks is 100.0% higher than that of the company.
Bone Biologics Institutional Holders
Institutional Holdings refers to the ownership stake in Bone Biologics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bone Biologics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bone Biologics' value.| Shares | Ubs Group Ag | 2024-06-30 | 33.7 K | Hrt Financial Llc | 2024-06-30 | 17.5 K | Tower Research Capital Llc | 2024-06-30 | 5.8 K | Mcmahon Financial Advisors, Llc | 2024-09-30 | 403 | Bank Of America Corp | 2024-06-30 | 9.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Armistice Capital, Llc | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Bone Fundamentals
| Return On Equity | -1.19 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | (339.2 K) | ||||
| Shares Outstanding | 2.46 M | ||||
| Shares Owned By Insiders | 5.21 % | ||||
| Shares Owned By Institutions | 4.58 % | ||||
| Number Of Shares Shorted | 72.06 K | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 0.85 X | ||||
| EBITDA | 479.57 K | ||||
| Net Income | (8.95 M) | ||||
| Cash And Equivalents | 5.45 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 831.4 K | ||||
| Current Ratio | 80.11 X | ||||
| Book Value Per Share | 5.44 X | ||||
| Cash Flow From Operations | (9.56 M) | ||||
| Short Ratio | 0.18 X | ||||
| Earnings Per Share | (1.46) X | ||||
| Target Price | 16.75 | ||||
| Beta | 0.74 | ||||
| Market Capitalization | 3.23 M | ||||
| Total Asset | 3.74 M | ||||
| Retained Earnings | (80.91 M) | ||||
| Working Capital | 2.91 M | ||||
| Current Asset | 1.07 M | ||||
| Current Liabilities | 2.16 M | ||||
| Net Asset | 3.74 M |
About Bone Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bone Biologics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bone Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bone Biologics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Bone Biologics Corp is a strong investment it is important to analyze Bone Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bone Biologics' future performance. For an informed investment choice regarding Bone Stock, refer to the following important reports:Check out Bone Biologics Piotroski F Score and Bone Biologics Valuation analysis. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bone Biologics. If investors know Bone will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bone Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.46) | Return On Assets (0.57) | Return On Equity (1.19) |
The market value of Bone Biologics Corp is measured differently than its book value, which is the value of Bone that is recorded on the company's balance sheet. Investors also form their own opinion of Bone Biologics' value that differs from its market value or its book value, called intrinsic value, which is Bone Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bone Biologics' market value can be influenced by many factors that don't directly affect Bone Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bone Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bone Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bone Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.